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Abstract: In recent years, there has been a major advance in the treatment of pulmonary 
hypertension. New medications are continually added to the therapeutic arsenal. The prostanoids 
are among the first agents used to treat pulmonary hypertension and are currently considered 
the most effective. This case study describes a 63-year-old man who was diagnosed with 
chronic thromboembolic pulmonary hypertension and successfully treated with subcutaneously 
administered treprostenil for 6 months before a successful pulmonary thromboendarterectomy. 
Treatment of chronic thromboembolic pulmonary hypertension often requires a multidisciplinary 
approach before surgery. Further evaluation of prostanoids is needed to define their role and 
time of initiation of medical therapy in these patients.
Keywords: chronic thromboembolic pulmonary hypertension, prostanoids, treprostenil sodium, 
pulmonary thromboendarterectomy
Introduction
Chronic thromboembolic pulmonary hypertension (CTEPH) has emerged as one of 
the leading causes of severe pulmonary hypertension.1–3 The disease is notoriously 
underdiagnosed, and its true prevalence is still unclear. However, with the development 
of improved therapeutic modalities, cardiologists and thoracic surgeons have shown 
increasing interest in the diagnostic work-up of this entity. The diagnosis and 
management of CTEPH requires a multidisciplinary approach involving the specialties 
of pulmonary medicine, cardiology, radiology, anesthesiology, and thoracic surgery. 
CTEPH is characterized by intraluminal thrombus organization and fibrous stenosis 
or complete obliteration of pulmonary arteries.
Due to clinically evident acute pulmonary embolism episodes being absent 
in .50% of patients, the diagnosis of CTEPH can be difficult. Computed tomography 
pulmonary angiogram is the gold standard test for diagnosing CTEPH and will show 
features of chronic pulmonary embolism. Another method used is the lung scintiscan 
showing segmental mismatched perfusion defects. Pulmonary angiography confirms 
the   diagnosis and determines the feasibility of endarterectomy according to the 
location of the disease (proximal versus distal). The technique of angiography must 
be perfect with the whole arterial tree captured on the same picture for each lung. 
The lesions must start at the level of the pulmonary artery trunk or at the level of the 
lobar   arteries, in order to find a plan for the endarterectomy. When the hemodynamic International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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gravity corresponds to the degree of obliteration, pulmonary 
thromboendarterectomy can be performed.4
CTEPH induces hypoxemia and pulmonary   hypertension, 
eventually leading to respiratory failure and right heart   failure. 
Treatment of CTEPH often requires a   multidisciplinary 
approach and may involve surgery, medical treatment, or 
both.5,6 Vascular disobliteration by pulmonary endarterectomy 
(PTE) is the preferred treatment for patients with CTEPH,7,8 
but not all patients are eligible for surgery.9 When surgical 
indications are carefully selected, pulmonary thromboendart-
erectomy using intermittent circulatory arrest under profound 
hypothermia is quite effective for treating CTEPH.
Case report
A 63-year-old man presented in the emergency department 
complaining of progressive dyspnea on exertion and signs 
of right heart dysfunction including fatigue and palpitations. 
The patient was an ex-smoker (25 pack-years), had a history 
of percutaneous transluminal coronary angioplasty 5 years 
previously, was on anticoagulant treatment (warfarin), and 
had an international normalized ratio level of 2.3 at the time 
of admission. He had decreased daily movement and was 
obligated to stop for rest every 100 meters of walking. He was 
in his usual state of health until 15 days before   presentation, 
when he noted the onset of bilateral lower extremity 
edema. His symptoms of fatigue, orthopnea,   paroxysmal 
  nocturnal dyspnea, and a productive cough of clear sputum 
had   progressed. His exercise tolerance had decreased from 
several kilometers to 10–20 meters at a walking pace of less 
than 100 meters.
Physical findings included a left parasternal heave, 
a prominent pulmonary component of S2, left block, and a 
systolic murmur of tricuspid regurgitation. He was hypoxic, 
hyperventilating (respiratory rate 30/minute), had low 
oxygen saturation (SpO2), and had signs of right heart   failure 
(extended neck veins, legs swelling, and acrocyanosis). 
At the time of admission, arterial blood gases on air were 
pH 7.46, partial pressure carbon dioxide 31 mmHg, partial 
pressure of oxygen 53 mmHg, and SpO2 89%. Blood gas 
analysis revealed a wide alveolar and arterial oxygen ten-
sion difference, which is typical for patients with CTEPH. 
His blood pressure was 100/90 mmHg. Chest x-ray revealed 
hyperlucency, diminished vasculature, and cardiomegaly 
with prominent central pulmonary arteries (Figure 1).
Transthoracic echocardiography was the initial   diagnostic 
tool that demonstrated enlarged right heart cavities with 
normal sized left ventricle, paradoxical movement of 
  interventricular septum, and severe pulmonary   hypertension 
(right ventricle systolic pressure [RVSP] 73 mmHg). The 
ventilation-  perfusion scanning demonstrated multiple 
  perfusion deficits in both lungs compatible with chronic 
thromboembolic disease (Figure 2). Diagnosis was supported 
by computed tomography angiography, which revealed 
eccentric thrombotic material within the main branch of 
the right pulmonary artery, the branches of the right lower 
lobe, and the descending branch of the left lung; subpleural 
densities; and a characteristic mosaic attenuation of the 
pulmonary parenchyma (Figure 3). Because a previous 
computed tomography angiogram was not available, it was 
presumed based upon the clinical findings that new emboli 
were formulated on established chronic thromboembolic 
disease. Although additional radiographic imaging with high-
resolution computed tomography can assist in establishing 
venoocclusive disease, this method was not performed.10,11 
The patient did not have severe hemodynamic instability and 
thrombolysis was not performed. Although acute pulmonary 
embolism may be clinically silent,12 there is accumulating 
evidence that CTEPH may also develop in the absence of 
Figure 1 Cardiomegaly and dilatation of right and left lung hilum. Increased vascular 
shadowing in both sides. Costophrenic regions free of pleural effusion.
Figure  2  High  probability  for  pulmonary  embolism  ventilation/perfusion  scan 
demonstrating normal ventilation and multiple mismatched segmental and larger 
defects more in the right lung. The rate of perfusion for the right and the left lung is 
27.4% and 72.4%, respectively.International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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previous pulmonary embolism.13 In these cases, the disease 
is probably initiated by thrombotic or inflammatory lesions 
in the pulmonary   vasculature. Once vessel   obliteration 
is   sufficient to cause increases in the pulmonary arterial 
pressure, a process of pulmonary vascular remodelling is 
started, which self-perpetuates the progression of pulmonary 
hypertension, even in the absence of further thromboembolic 
events.14
Additional procoagulant work-up included activated 
partial thromboplastin time with a reference range of 
18–28 seconds; antiphospholipids with immunoglobulin 
(Ig)M and IgG anticardiolipin antibodies measured by 
enzyme-linked immunosorbent assay, levels .20 MPL/GPL 
considered positive; anti-ß2 glycoprotein I levels measured 
by enzyme-linked immunosorbent assay, .20 SMU/GMU 
considered positive; lupus anticoagulant test detected using 
dilute Russell’s viper venom assay and confirmed with 1:1 
dilution of plasma from patients with normal plasma to rule 
out factor deficiencies and confirm phospholipid dependency; 
protein C; protein S; antithrombin III, factor V Leiden; 
homocysteine; and prothrombin gene mutation. The work-up 
came back negative twice during the patient’s hospitalization. 
Further investigations for autoimmunity, collagen vascular 
diseases, hemoglobinopathies, HIV infection, drug or toxin 
use, and sleep apnea were negative.
At the time of the patient’s admission he was in class IV 
based on the classification of the New York Heart Association 
(NYHA). The patient was treated with long-term oxygen 
therapy, diuretics, and anticoagulants (acenocoumarol) 
adjusted to a target international normalized ratio between 
2.0 and 3.0. An evaluation of the patient was performed in the 
initial days after the admission, after prompt   treatment was 
administered. At this stage, spirometry results were forced 
expiratory volume in 1 second 2.55 L (80%), forced vital 
capacity 3.42 L (83%), total lung capacity 5.27 L (76%), 
residual volume 2.26 L (92%), functional residual   capacity 
2.72 L (76%), and carbon monoxide diffusing   capacity 14.9 L 
(54%). The patient’s 6 minute walking distance (6MWT)   
was 240 meters, and desaturation was from 91% to 85%. 
His ergospirometry findings were consistent with very poor 
Figure 3 Computed tomographic angiogram demonstrating findings of chronic pulmonary embolism and showing occlusive thrombus in the right pulmonary artery and its 
branches for the right lower lobe. Embolus within the left main pulmonary artery extending into the lobar branches. Small pericardial effusion, enlarged right ventricle, and 
congestion of inferior vena cava and hepatic veins.International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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prognosis (arterial blood   pressure fixation and reduced 
maximum oxygen   consumption (42% predicted with no 
desaturation). The gold standard to   properly investigate 
pulmonary hypertension is with right heart catheterization 
to assess the pulmonary pressures and pulmonary capillary 
wedge pressure. The patient had two relative contraindica-
tions, the anticoagulant therapy and NYHA IV , but also a 
complete contraindication of left bundle branch block (due 
to the risk of complete heart block).
To decrease the pulmonary pressure further, treatment 
with subcutaneous administration of treprostinil sodium was 
initiated and titrated to a final dose of 35 ng/kg/  minute because 
efficacy of this treatment had already been   demonstrated 
in previous studies.15–18 The patient   demonstrated rapid 
improvement of his hemodynamic parameters and 6MWT.   
There was a decrease in RVSP to 60 mmHg and also a further 
improvement in 6MWT to 450 meters but with a desaturation 
from 91% to 87%. According to NYHA, the patient at that 
moment was in class II–III. The patient tolerated the drug 
well without side effects. His only complaints were of mild 
erythema and local pain and pain in the lower jaw at the start 
of mastication for 3 weeks.
After 6 months of medical therapy the patient met the 
established criteria for PTE, including mean pulmonary 
artery pressure .25 mmHg, .3 months of effective oral 
anticoagulation, evidence of surgically accessible thrombi, 
a beneficial relationship between pulmonary vascular 
resistance and the anticipated thrombus mass, no comor-
bidities, and no severe reduction in lung function (Table 1). 
The surgery was successful. The patient no longer needed 
  oxygen therapy, RVSP decreased to 35 mmHg, and 6MWT   
increased to 490 meters. No further invasive assessments of 
hemodynamics were performed.
Discussion
Chronic thromboembolism is a frequent cause of progres-
sive hypertension and carries a poor prognosis. In CTEPH, 
pathological lesions are characterized by organized thrombi 
tightly attached to the pulmonary arterial medial layer in 
the elastic pulmonary arteries, replacing the normal intima. 
These may completely occlude the lumen or form different 
grades of stenosis, webs, and bands.19 Interestingly, in the 
nonoccluded areas, a pulmonary arteriopathy indistinguish-
able from that of pulmonary arterial hypertension (including 
plexiform lesions) can develop.20 Collateral vessels from the 
systemic circulation (from bronchial, costal, diaphragmatic, 
and coronary arteries) can grow to reperfuse, at least partially, 
the areas distal to complete obstructions.
The true incidence and prevalence of CTEPH are 
unknown. Originally, it was believed that 0.1%–0.5% of 
patients who survive an episode of acute pulmonary embo-
lism develop CTEPH.21–23 Defining the true incidence of 
CTEPH is hampered by the observation that up to two-thirds 
of these patients have no history of clinically overt acute 
pulmonary embolism.15–24 It is not clear to what degree the 
eventual development of CTEPH is determined by each 
recurrent thromboembolic event, in situ thrombosis, or 
other changes in the vasculature distal to the vessels initially 
obstructed by clot.4
In addition to recanalized clot, histological changes 
  similar to those seen in other forms of pulmonary hyperten-
sion have been identified in patients with CTEPH. Patients 
with CTEPH have symptoms of progressive dyspnea, 
fatigue, and   presyncope or loss of consciousness similar to 
the symptoms of patients with other forms of pulmonary 
hypertension.25 Many are unaware of prior venous throm-
boembolic events, and diagnosis is appreciably delayed while 
other causes of dyspnea are pursued and possibly treated.8 
Findings that might narrow consideration of CTEPH are 
chronic postphlebitic changes of the lower extremity and 
the presence of pulmonary flow murmurs, described as 
high pitched and best heard over the lung fields during an 
inspiratory breath-hold. Recognition of the diagnosis usu-
ally follows identification of pulmonary hypertension on the 
echocardiogram and evidence of chronic thromboembolic 
disease by ventilation-perfusion   scanning or pulmonary 
angiography.7 Other techniques include contrast-enhanced 
magnetic resonance (MR) angiography, MR   perfusion imag-
ing, phase-contrast imaging of the great vessels, cine imaging 
of the heart, and combined perfusion-ventilation MR imaging 
with hyperpolarized noble gases. It is anticipated that MR 
Table 1 Patient’s clinical history
Admission First 
month
Sixth  
month
Eleventh 
month
Surgery
NYHA IV III II–III I
Dose (ng/kg/minute) 1.25 7.5 35 0
6MWT (meters) 240 360 450 490
SpO2 (resting, %) 88 90 89 93
SpO2 (minimum, %) 86 88 87 90
RVSP (mmHg) 73 67 60 35
VO2 (maximum,  
% predicted)
42 46
AT (% predicted) 31 42
Abbreviations: 6 minute walking test; AT, anerobic threshold; NYHA, New York 
Heart Association; RVSP, right ventricle systolic pressure; SpO2, oxygen saturation; 
VO2, oxygen consumption.International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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imaging will play a central role in the initial diagnosis and 
follow-up of patients with CTEPH.26
PTE is the definitive treatment for chronic pulmonary 
hypertension resulting from thromboembolic disease.5,6,9 
  Pulmonary thromboendarterectomy can markedly reduce 
and even normalize pulmonary hemodynamics. The major-
ity of patients experience improvements in exercise capacity, 
gas exchange, World Health Organization functional class, 
and quality of life. In a retrospective follow-up of more than 
500 patients who underwent pulmonary thromboendarterec-
tomy at the University of California, San Diego between 1970 
and 1994, the probability of survival beyond 6 years was 75 
percent.27 Although direct comparison between populations and 
centers has not been performed, survival at 5 years of patients 
who were treated with anticoagulation alone in separate series 
was less than 30 percent.28,29
However, CTEPH may be inoperable owing to surgi-
cally inaccessible thrombi or comorbid diseases that confer 
an unacceptably high risk. Pharmacotherapies, although not 
yet approved, may be useful in this situation or for treating 
residual or recurrent pulmonary hypertension following 
surgery. Vasodilator drugs for pulmonary hypertension are 
attracting growing interest as potential treatments for CTEPH, 
because this disease has recently been labelled as a “dual” 
pulmonary vascular disorder of major vessel obstruction, and 
remodelling is combined with small vessel arteriopathy that is 
histologically indistinguishable from the classical pulmonary 
arteriopathy observed in pulmonary arterial hypertension. 
Several uncontrolled clinical studies suggest that prostanoids, 
endothelin-receptor antagonists, and phosphodiesterase type 
5 inhibitors may exert hemodynamic and clinical benefits in 
patients with CTEPH, regardless of whether these patients 
were considered operable or inoperable.30–35
The only randomized, placebo-controlled clinical trial 
that has so far addressed the safety and efficacy of medical 
treatment was BENEFIT (Bosentan Effects in Inoperable 
Forms of Chronic Thromboembolic Pulmonary Hyperten-
sion Trial). BENEFIT employed the dual endothelin-receptor 
antagonist bosentan. Although hemodynamics improved 
significantly, the second component of the primary endpoint, 
exercise capacity, was not met. More evidence is required 
to resolve whether vasodilator treatments are beneficial for 
inoperable CTEPH.15–18,36 Given these limited data, further 
studies are necessary to obtain reliable long-term data on the 
effects of medical therapies in patients with CTEPH, and 
these patients should be treated within clinical trials whenever 
possible. For the present time, no medical therapy has been 
approved in Europe or the US for CTEPH.
Conclusion
Recent research suggests that the mechanistic view of 
CTEPH as a disease caused solely by obliteration of central 
pulmonary arteries due to organized thrombi may have 
been too simplistic. Pulmonary embolism, either as a single 
episode or recurrent phenomena, is still thought to be the 
initiating event in many patients. However, the mechanisms of 
progressive pulmonary vascular remodelling are still poorly 
understood, and treatment of CTEPH requires a multidisci-
plinary approach.
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